slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
221,521-221,550 of 319,975
44
Includes spider plots/swimmer-style plots for tumor response and bar charts for best percentage change.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
45
The slide uses a scatter plot to map clinical trials and a table to summarize treatment outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
46
The slide presents clinical data for a small sample size (n=4) in a highly pre-treated patient population.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
47
Shows two parallel tracks: monotherapy and combination therapy with tislelizumab.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
48
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
49
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
50
The slide uses a process-to-product mapping structure.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
51
Includes technical diagrams of the drug delivery vehicle and comparative histology/survival data.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
52
Includes two sets of charts: tumor volume over time and survival curves.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
53
Includes multiple citations and diagrams illustrating the mechanism of action and clinical efficacy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
54
The slide uses a numbered list format to present key value propositions for the company's pipeline.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
55
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
56
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
57
The slide uses a serpentine process flow (1-5 left-to-right, 6-10 right-to-left).Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
58
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
59
The slide uses a combination of expert testimonials and a comparative table of clinical trials to validate the outpatient administration model.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
60
The slide uses a bar chart to contrast the combined sales of two groups of drugs, implying a large market opportunity for TSTx.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
61
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
01
Innoviva | Results Presentation Deck | 7 slidesInnoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · Attention1 hit
02
Headline doubles as action title with a positive-result takeaway; body is a pure bulleted summary with footnoted Lancet citations and Innoviva branding bottom-right.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
03
The diagram illustrates a randomized controlled trial structure.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
04
Flowchart shows patient progression from screening to dosing and categorization by infection site.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
05
Clinical trial results presentation.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
06
The slide highlights that these secondary analyses were not powered for statistical significance.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
07
The slide uses a split-layout with key takeaways on the left and supporting clinical data tables on the right.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
01
Innoviz | Results Presentation Deck | 20 slidesInnoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Setup1 hit
02
Innoviz | Results Presentation Deck | 20 slidesInnoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Setup1 hit
03
Innoviz | Results Presentation Deck | 20 slidesInnoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Setup1 hit
04
Innoviz | Results Presentation Deck | 20 slidesInnoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Setup1 hit
05
The slide uses a split layout with a dark sidebar for branding and a large photo of the vehicle on the right.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Key Takeaways1 hit